About EvolutionaryScale
EvolutionaryScale is a company based in New York (United States) founded in 2023 by Thomas Hayes, Tom Sercu, Halil Akin, Roshan Rao, and Alexander Rives. EvolutionaryScale has raised $142 million across 1 funding round from investors including Amazon, Nat Friedman and Daniel Gross. EvolutionaryScale operates in a competitive market with competitors including Nimbus Therapeutics, Cradle, Evozyne, Profluent Bio and Frontier Medicines, among others.
- Headquarter New York, United States
- Founders Thomas Hayes, Tom Sercu, Halil Akin, Roshan Rao, Alexander Rives
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sinapsis Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$142 M (USD)
in 1 rounds
-
Latest Funding Round
$142 M (USD), Seed
Jun 25, 2024
-
Investors
Amazon
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of EvolutionaryScale
EvolutionaryScale has successfully raised a total of $142M through 1 strategic funding round. The most recent funding activity was a Seed round of $142 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in EvolutionaryScale
EvolutionaryScale has secured backing from 5 investors, including angel, venture fund, and institutional investors. Prominent investors backing the company include Amazon, Nat Friedman and Daniel Gross.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early-stage technology companies are funded by Lux Capital.
|
Locked | Locked | Locked | |
|
Venture capital arm of Nvidia
|
Locked | Locked | Locked | |
|
Multi-category products are offered through an online marketplace.
|
Locked | Locked | Locked |
Investor details for EvolutionaryScale
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EvolutionaryScale
Investment portfolio details for EvolutionaryScale
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - EvolutionaryScale
Detailed financials for EvolutionaryScale
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Evolutionaryscale Comparisons
Peer comparison for EvolutionaryScale
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EvolutionaryScale
EvolutionaryScale operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Cradle, Evozyne, Profluent Bio and Frontier Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Chemoproteomics solutions are provided for protein design and development.
|
|
| Locked | Locked | Locked |
Developer of proteins using protein engineering technology
|
|
| Locked | Locked | Locked |
An AI-based protein design platform is provided for drug discovery.
|
|
| Locked | Locked | Locked |
Bioinformatics platform is developed for drug discovery and chemoproteomics.
|
Detailed competitors of EvolutionaryScale
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Evolutionaryscale
Complete news archive for EvolutionaryScale
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EvolutionaryScale
EvolutionaryScale was founded in 2023 and raised its 1st funding round 1 year after it was founded.
EvolutionaryScale is headquartered in New York, United States. It is registered at New York, New York, United States.
Alexander Rives is the current CEO of EvolutionaryScale. They have also founded this company.
EvolutionaryScale is a funded company, having raised a total of $142M across 1 funding round to date.
EvolutionaryScale was founded in 2023 and is headquartered in New York, United States. Operations focus on the biotechnology sector, where AI-driven models for protein engineering are provided. The companys ESM3 model is utilized to analyze protein sequences, structures, and functions simultaneously. Services support research in biological applications, with a team of co-founders leading development efforts.
EvolutionaryScale's top competitors include Nimbus Therapeutics, Cradle and Profluent Bio.
EvolutionaryScale has 5 investors. Key investors include Amazon, Nat Friedman, Daniel Gross, Lux Capital, and NVentures.